A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.
Joanne M LangleyTerry M NolanMika RämetPeter C RichmondNelson Rosário FilhoWouter HaazenSara P H van den BergKristi WilliamsArangassery Rosemary BastianEdmund OmoruyiJoanna Williams DurkinNadine SalischGunter Van GeetWilbert van DuijnhovenEsther HeijnenBenoit CallendretPublished in: Open forum infectious diseases (2024)
Ad26.RSV.preF was well tolerated and immunogenic in RSV-seronegative toddlers.